INTRODUCTION {#s1}
============

Kidney fibrosis is a hallmark of chronic kidney disease. It is characterized by the accumulation of myofibroblasts and excessive deposition of extracellular matrix components. Myofibroblasts are the key effectors in the development and progression of kidney fibrosis. The cellular origins of myofibroblasts are diverse, including resident fibroblasts, fibrocytes from bone marrow, pericytes and perivascular fibroblasts \[[@gfw308C1]--[@gfw308C4]\]. Importantly, renal endothelial cells have been shown to contribute to kidney fibrosis via endothelial--mesenchymal transition (EndoMT) \[[@gfw308C2], [@gfw308C3], [@gfw308C5]\].

Matrix metalloproteinase 9 (MMP-9), also known as gelatinase B, has been proven by us and others to cause kidney fibrosis \[[@gfw308C6], [@gfw308C7]\]. We have demonstrated that MMP-9 induced epithelial-mesenchymal transition (EMT) in rat proximal tubular epithelial (NRK52E) cells downstream of TGF-β1 and that MMP-9 of macrophage origin is responsible for TGF-β1-induced EMT in murine tubular epithelial (C1.1) cells \[[@gfw308C6], [@gfw308C7]\]. Recently, we found that MMP-9 also induced EndoMT in human glomerular endothelial cells (unpublished data), but the underlying mechanisms remains unknown.

EndoMT occurs during organ development, and under pathological conditions such as cardiac and pulmonary fibrosis, and during the recruitment of carcinoma-associated fibroblasts \[[@gfw308C8]--[@gfw308C11]\]. EndoMT is characterized by down-regulation of cell--cell contact and endothelial markers including CD31 and vascular endothelial cadherin (VE-cadherin), and up-regulation of mesenchymal markers such as fibroblast-specific protein (FSP-1) and α-smooth muscle actin (α-SMA) \[[@gfw308C12]\]. LeBleu *et al.* showed that ∼10% of interstitial myofibroblasts expressed markers of both endothelial cells and activated fibroblasts in lineage-tagged transgenic mice after unilateral ureteral obstruction (UUO) \[[@gfw308C5]\]. Zeisberg and colleagues reported that 30--50% of myofibroblasts in kidney fibrosis co-expressed the endothelial marker CD31 and the fibroblast/myofibroblast markers FSP-1 and/or α-SMA \[[@gfw308C13]\]. However, the exact origin of the endothelial cells (glomerular, peritubular or vascular) is uncertain, and the mechanisms and signaling pathways that control EndoMT are largely unknown.

Notch signaling is a highly conserved pathway that regulates cell fate. Notch proteins including Notch-1 to -4, and their ligands Jagged-1, 2 and Delta like (Dll)-1, 3 and 4, are all transmembrane proteins \[[@gfw308C14]\]. Upon ligand binding, Notch intracellular domain (NICD) is released by proteolytic cleavage via presenilin-/gamma-secretase \[[@gfw308C15]\], and translocates to the nucleus. Once in the nucleus, NICD converts the transcription repressor CSL \[CBF1/Su(H)/lag2\] to a transcription activator, which promotes the expression of a set of target genes including *HES* and *HERP* \[[@gfw308C16]\]. The Notch signaling pathway has been shown to act downstream of vascular endothelial growth factor (VEGF) signaling to regulate the morphogenesis of endothelial cells by activating specific MMPs \[[@gfw308C17]\]. In addition, activation of Notch in endothelial cells results in morphological, phenotypic and functional changes consistent with mesenchymal transformation \[[@gfw308C18]\]. Inhibition of Notch signaling by gamma-secretase inhibitor (GSI) ameliorates tubulointerstitial fibrosis in mouse models \[[@gfw308C19]\]. Moreover, silencing of Notch-1 protein leads to down-regulation and inactivation of VEGF and MMP-9, thereby inhibiting invasion and metastasis of pancreatic cancer cells \[[@gfw308C20]\]. However, the relationship between the Notch signaling pathway and MMPs in EndoMT and fibrosis is poorly understood.

The aim of this study was to investigate the contribution of MMP-9 to EndoMT of mouse renal peritubular endothelial cells (MRPECs) and kidney fibrosis, and the relationship between Notch signaling and MMP-9 in EndoMT.

MATERIALS AND METHODS {#s2}
=====================

Animals and UUO {#s2a}
---------------

Male BALB/c mice ∼6 weeks old were purchased from the Australian Research Center (Perth, Australia). MMP-9 knockout (KO) mice crossed into a BALB/c background were kindly provided by Prof. Zena Werb of University of California via Prof. Erick Thompson of Melbourne University. Experiments were carried out in accordance with the protocols approved by the Animal Ethics Committee of Western Sydney Local Health District. Kidney fibrosis was induced by UUO as previously described \[[@gfw308C21]\]. Sham-operated mice underwent the same surgical procedure except for the ureteral ligation. A total of six mice were used in each control and experimental group. Kidneys were harvested at 2 weeks after UUO.

Cell culture and treatment {#s2b}
--------------------------

Primary MRPECs were isolated from kidneys as described previously \[[@gfw308C22]\], and cultured at 37°C in 5% CO~2~ in endothelial cell medium (ScienCell, Carlsbad, CA, USA) supplemented with 5% fetal bovine serum (ScienCell), 1% epithelial growth supplement (ScienCell) and 1% penicillin/streptomycin (ScienCell) and 2.5--5 µg/mL VEGF (Sigma-Aldrich, St Louis, MO, USA). MRPECs were cultured at low density in fibronectin pre-coated flasks or plates the day before treatment. The cells were then washed with phosphate-buffered saline (PBS) and cultured in serum-free endothelial cell medium with rhTGF-β1 (5 and 10 ng/mL; Invitrogen, Carlsbad, CA, USA) alone, with rhTGF-β1 and MMP-9 inhibitor I (0.05, 0.25 and 0.5 nmol/mL; Merck Chemicals, Darmstadt, Germany) \[[@gfw308C23]\], with recombinant human MMP-9 (rhMMP-9) (2 µg/mL; Biomol International, Plymouth Meeting, PA, USA), or rhTGF-β1 and GSI (0.05 and 0.1 nmol/mL).

Immunofluorescence analysis {#s2c}
---------------------------

Cells were seeded onto glass coverslips placed in 6-well plates and cultured until they reached 50--60% confluence. Cells were then washed with PBS and fixed with cold absolute methanol for 10 min at −20°C. Fixed cells were washed with PBS and blocked with 2% bovine serum albumin (BSA; Sigma-Aldrich) in PBS for 1 h at room temperature. Cells were then incubated with primary antibodies against endothelial cell marker rabbit polyclonal anti-VE-cadherin (1:200; Alexis Biochemicals, Farmingdale, NY, USA) and mesenchymal marker mouse monoclonal anti-α-SMA (1:200; Sigma-Aldrich) in 2% BSA in PBS for 1 h at room temperature. Secondary fluorescent-conjugated anti-rabbit Alexa Fluor^®^ 488 (1:600; Invitrogen) was used for VE-cadherin and anti-mouse Alexa Fluor^®^ 546 (1:600; Invitrogen) was used for α-SMA for 40 min at room temperature in dark, followed by washing in PBS and distilled water and counterstaining with 4′,6-diamidino-2-phenylindole (DAPI; Invitrogen) for 5 min. They were then washed in PBS and distilled water before mounting with fluorescence mounting medium (Dako, Glostrup, Denmark) for visualization by fluorescence microscopy. For antibody isotype controls, rabbit IgG2a κ purified (eBioscience, San Diego, CA, USA) was used for VE-cadherin staining and mouse IgG2a κ (Biolegend, San Diego, CA, USA) was used for α-SMA staining, and their corresponding secondary antibodies were applied.

For tissue staining, frozen blocks from kidney were cut into 5 µm sections and fixed with ice-cold acetone at −20°C for 10 min and blocked with 2% BSA for 1 h. Double immunofluorescence staining was performed using the following combinations of antibodies: VE-cadherin and α-SMA, Hey-1 (1:150; Abcam, Cambridge, UK) and α-SMA. Tissue sections were sequentially incubated with a single primary antibody followed by its corresponding fluorescence-conjugated secondary antibody. Tissue sections were washed three times with PBS between each staining and counterstained with DAPI for 5 min before mounting with the fluorescence mounting medium. Rabbit IgG (Invitrogen) was used as a negative control for Hey-1. Images were obtained using a fluorescence microscope (Zeiss, Jena, Germany) at ×200 magnification.

Western blot analysis {#s2d}
---------------------

Protein lysates from equal numbers of cultured cells were obtained by Tris-glycine SDS sample buffer (Gradipore, Frenchs Forest, Australia) and homogenized by drawing five times through a 0.5 mL insulin syringe. Equal quantities of protein were loaded per lane on 12-well NuPAGE 4--15% Bris-Tris gels (Bio-Rad, Hercules, CA, USA) for electrophoresis under reduced conditions. After electrophoresis, the proteins were transferred onto polyvinylidene difluoride membrane (Bio-Rad) using Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad). For immunodetection, membranes were blocked in 5% skim milk in PBS overnight at 4°C and incubated for 2 h at room temperature with primary antibodies prepared in blocking buffer: mouse monoclonal anti-α-SMA (1:300, Sigma-Aldrich), rabbit polyclonal anti-VE-cadherin (1:1000; Alexis Biochemicals), mouse monoclonal anti-CD31 (1:1000; Cell Signaling Technology, Boston, MA, USA), mouse monoclonal anti-NICD (1:1000; Merck Millipore, Billerica, MA, USA), rabbit monoclonal anti-Notch-1 (1:1000; Cell Signaling Technology), rabbit monoclonal anti-vimentin (1:1000; Cell Signaling Technology), mouse monoclonal anti-collagen I (Col-I) and goat polyclonal anti-fibronectin (FN1) antibody (1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The membranes were washed three times (10 min per wash on a rocking platform) and incubated for 1 h with their respective horseradish peroxidase (HRP)-conjugated secondary antibodies: goat anti-mouse HRP and goat anti-rabbit HRP (1:5000; Cell Signaling Technology). The membranes were washed three times (10 min per wash on a rocking platform) and bands were visualized with an enhanced chemiluminescence detection kit (Invitrogen). Mouse monoclonal anti-β-actin antibody (1:1000; Cell Signaling Technology) was used as the control for each sample.

Gelatin zymography {#s2e}
------------------

MMP-9 activity in a medium derived from rhTGF-β1-treated MRPECs was determined by gelatin zymography. Briefly, the medium was mixed with Tris-Glycine SDS Native Sample Buffer (1:1; Invitrogen) and electrophoresed through 10% Novex Zymogram Gelatin Gels (Invitrogen) with Tris-Glycine SDS Running Buffer (Invitrogen) under constant voltage of 125 V for 120 min. The gel was then incubated in Zymogram Renaturing Buffer (Invitrogen) for 30 min at room temperature with gentle agitation and washed with developing buffer (Invitrogen) for 30 min. The gel was further incubated for 24 h in fresh developing buffer at 37°C. After being developed, the gel was stained with 0.5% (w/v) Coomassie Blue R-250 (Bio-Rad) in 50% (v/v) methanol, 10% (v/v) acetic acid for 30 min at room temperature, and destained as described previously \[[@gfw308C24]\]. Gelatinolytic activity of MMP-9 was visualized as a clear band on a blue background. Band intensity was quantified by densitometry using the ImageJ software. Briefly, zymogram gels were scanned using Kodak Gel Logic 100 imaging system and processed into gray scale. Gray scale images were quantified densitometrically by the measurement of the mean intensity of positive band multiplied by its corresponding area. The optical band intensity was then corrected by subtracting the background intensity of equal area.

Histological analysis {#s2f}
---------------------

Tissue sections were stained for fibrosis using Gomori trichrome. For histological quantitation, a minimum of 15 non-overlapping images of cortex were taken under ×200 magnification for each kidney unless otherwise specified, and quantitated in a blinded manner. Quantitation for Gomori trichrome staining was performed by a modified grid-counting method adapted from Vielhauer *et al.* \[[@gfw308C25]\].

Statistical analysis {#s2g}
--------------------

Results from at least three independent experiments were expressed as means ± SEM. Statistical significance was evaluated using a two-tailed *t*-test for comparison between two groups, whereas one-way analysis of variance was used for the comparison of multiple groups. P \< 0.05 was considered significant.

RESULTS {#s3}
=======

Peritubular endothelial cells undergo mesenchymal transition after UUO {#s3a}
----------------------------------------------------------------------

To localize peritubular endothelial cells in mouse kidney tissue, we stained the specific endothelial cell marker VE-cadherin by immunofluorescence. As expected, the glomerular endothelial cells were stained positive (Figure [1](#gfw308F1){ref-type="fig"}A and C). Extensive VE-cadherin-positive cells were also found in the peritubular space in a normal kidney tissue (Figure [1](#gfw308F1){ref-type="fig"}A and C). To examine whether peritubular endothelial cells might contribute to fibrosis by EndoMT, we stained both VE-cadherin and α-SMA in the obstructed kidney of UUO mice. The results showed that VE-cadherin and α-SMA double positive cells were found in the peritubular capillary space outside the glomeruli (Figure [1](#gfw308F1){ref-type="fig"}F), indicating that EndoMT-derived myofibroblasts were localized within the peritubular interstitium and were distinct from other vascular endothelial cells by their histological location. These results provide direct evidence for the involvement of peritubular endothelial cells in EndoMT leading to kidney fibrosis. FIGURE 1Peritubular endothelial cells exhibit EndoMT in mice with UUO. (**A**--**C**) Kidney sections from sham-operated mice were stained using an immunofluorescent antibody against VE-cadherin (A: green) to detect endothelial cells and an immunofluorescent antibody against α-SMA to detect myofibroblasts (B: red). (C) Overlay of VE-cadherin, α-SMA and nuclear staining DAPI (blue). (**D**--**F**) Kidney sections from mice with UUO were stained with VE-cadherin (D: green) and α-SMA (E: red). (F) Overlay of the VE-cadherin, α-SMA and DAPI (blue) staining. Orange staining indicated VE-cadherin and α-SMA double positive cells in peritubular space away from glomeruli. Original magnification ×200.

TGF-β1 induces EndoMT and fibrosis markers in MRPECs via MMP-9 {#s3b}
--------------------------------------------------------------

To establish an *in vitro* model of peritubular EndoMT, subconfluent primary MRPECs isolated from mouse kidney were treated with rhTGF-β1 (5 and 10 ng/mL) for 24 h. These isolated primary MRPECs have been proved to be peritubular endothelial cells by staining of panendothelial cell antigen (PV-1) and other markers \[[@gfw308C22]\]. Endothelial marker CD31 and VE-cadherin as well as mesenchymal marker α-SMA and vimentin expression were determined by western blot. The expression of fibrosis markers, Col-I and FN was also detected by western blot analysis. We found that rhTGF-β1 at the concentration of 10 ng/mL significantly reduced CD31 and VE-cadherin proteins, while rhTGF-β1 at the concentration of both 5 and 10 ng/mL increased the expression of α-SMA and vimentin (Figure [2](#gfw308F2){ref-type="fig"}A). Immunofluorescence staining also demonstrated that 10 ng/mL rh-TGF-β1 treatment reduced VE-cadherin and increased α-SMA in MRPECs (Figure [2](#gfw308F2){ref-type="fig"}B). Accordingly, Col-I and FN expressions were markedly induced by rhTGF-β1 at both concentrations (Figure [2](#gfw308F2){ref-type="fig"}C). These results demonstrate that rhTGF-β1 is sufficient to induce EndoMT and fibrosis in MRPECs. FIGURE 2MMP-9 is involved in TGF-β1-induced EndoMT in MRPECs. (**A**) Representative western blots and quantitation of CD31, α-SMA, VE-cadherin and vimentin in MRPECs treated with rhTGF-β1 (5 and 10 ng/mL). β-actin was used as the loading control. (**B**) Immunofluorescence staining of α-SMA (red) and VE-cadherin (green) with nuclear stain (DAPI, blue) in MRPECs treated with 10 ng/mL rhTGF-β1. Original magnification ×200. (**C**) Representative western blots and quantitation of Col-I and FN in MRPECs treated with rhTGF-β1 (5 and 10 ng/mL). β-actin was used as the loading control. (**D**) Representative western blots and quantitation of CD31, VE-cadherin and α-SMA in MRPECs treated or not with rh-TGF-β1 (10 ng/mL) and MMP-9 inhibitor I (0.05, 0.25 and 0.5 nmol/mL). (**E**) MMP-9 expression examined by gelatin zymography of lysate of MRPECs treated with rh-TGF-β1. Data in bar graphs are means ± SEM (*n* ≥ 3 for each group). \*P \< 0.05 versus MRPECs without rhTGF-β1 treatment. ^†^P \< 0.05 versus MRPECs treated with 10 ng/mL rhTGF-β1.

To test whether MMP-9 is involved in TGF-β1-induced EndoMT, MRPECs were treated with 10 ng/mL rhTGF-β1 alone or in the presence of increasing concentrations of MMP-9 inhibitor I for 24 h. We found that MMP-9 inhibitor I abolished rhTGF-β1-induced reduction of CD31 and VE-cadherin and the induction of α-SMA in a dose-dependent manner (Figure [2](#gfw308F2){ref-type="fig"}D). Furthermore, zymography showed that MMP-9 activity was increased after rhTGF-β1 treatment (Figure [2](#gfw308F2){ref-type="fig"}E). These results demonstrate that TGF-β1-induced EndoMT is mediated, at least in part, through MMP-9.

MMP-9 induces EndoMT and fibrotic markers in MRPECs {#s3c}
---------------------------------------------------

To determine whether MMP-9 contributes to EndoMT and fibrosis, we incubated subconfluent MRPECs with 2 µg/mL rhMMP-9 for 48 h and examined the expression of endothelial and mesenchymal markers as well as fibrotic markers by western blot and immunofluorescence staining. We showed that rhMMP-9 significantly decreased the levels of endothelial markers CD31 and VE-cadherin while increasing mesenchymal markers α-SMA and vimentin when compared with control MRPECs (Figure [3](#gfw308F3){ref-type="fig"}A and B). Consistently, immunofluorescence staining demonstrated that rhMMP-9 reduced VE-cadherin and increased α-SMA expression (Figure [3](#gfw308F3){ref-type="fig"}C). rhMMP-9 treatment also significantly up-regulated Col-I and FN expression (Figure [3](#gfw308F3){ref-type="fig"}D). Thus, MMP-9 alone is sufficient to induce EndoMT and fibrosis in MRPECs. FIGURE 3rhMMP-9 alone induces EndoMT of MRPECs. (**A**) Representative CD31, VE-cadherin, α-SMA and vimentin expression in MRPECs treated with or without 2 µg/mL rhMMP-9 for 48 h measured by western blot. (**B**) Quantitation of CD31, VE-cadherin, α-SMA and vimentin expression in MRPECs treated with or without 2 µg/mL rhMMP-9 for 48 h. (**C**) Representative immunofluorescence staining of α-SMA (red) and VE-cadherin (green) with nuclear counter stain (DAPI, blue) of MRPECs treated with or without 2 µg/mL rhMMP-9 for 48 h. (**D**) Representative western blots and quantitation of Col-I and FN in MRPECs treated with or without 2 µg/mL rhMMP-9 for 48 h. Original magnification ×200. Data in bar graphs are means ± SEM (*n* ≥ 3 for each group). \*P \< 0.05 versus MRPECs without rhMMP-9 treatment.

TGF-β1-induced EndoMT is decreased in MMP-9-deficient MRPECs {#s3d}
------------------------------------------------------------

To further examine the role of MMP-9 in EndoMT and fibrosis induced by TGF-β1 in MRPECs, MRPECs derived from MMP-9 KO and wild-type (WT) control mice were treated with 10 ng/mL rhTGF-β1. Western blot analysis showed that MMP-9 deficiency significantly attenuated rhTGF-β1-induced increase of α-SMA, Col-I and FN and decrease of CD31 and VE-cadherin (Figure [4](#gfw308F4){ref-type="fig"}A and B). Immunofluorescence staining confirmed that rhTGF-β1-induced EndoMT was significantly reduced in MMP-9 KO MRPECs compared with that of WT controls (Figure [4](#gfw308F4){ref-type="fig"}C). Interestingly, rhTGF-β1-induced EndoMT was accompanied by a dramatic increase of NICD and decrease of Notch-1 in WT MRPECs (Figure [4](#gfw308F4){ref-type="fig"}A and B). However, this TGF-β1-induced Notch signaling was reduced in MMP-9-deficient MRPECs (Figure [4](#gfw308F4){ref-type="fig"}A and B). These results suggest that the effect of MMP-9 on TGF-β1-induced EndoMT is achieved via the Notch pathway. FIGURE 4TGF-β1-induced EndoMT and activation of Notch pathway are reduced in MMP-9-deficient MRPECs. (**A**) Representative western blots of CD31, VE-cadherin, α-SMA, NICD, Notch-1, Col-I and FN in MRPECs derived from MMP-9 KO mice or WT controls treated with or without 10 ng/mL rhTGF-β1 for 48 h. (**B**) Quantitation of CD31, VE-cadherin, α-SMA, NICD, Notch-1, Col-I and FN in MRPECs derived from MMP-9 KO mice or WT controls treated with or without 10 ng/mL rhTGF-β1 for 48 h. (**C**) Indirect immunofluorescence staining of VE-cadherin and α-SMA in primary MRPECs derived from MMP-9 KO mice or WT controls treated with or without 10 ng/mL TGF-β1 for 48 h. Original magnification ×200. Data in bar graphs are means ± SEM (*n* ≥ 3 for each group). \*P \< 0.05 versus corresponding MRPECs without rhTGF-β1 treatment. ^†^P \< 0.05 versus MRPECs derived from MMP-9 WT mice.

Inhibition of Notch attenuates rhMMP-9-induced EndoMT in MRPECs {#s3e}
---------------------------------------------------------------

To confirm that the Notch pathway is involved in MMP-9-induced EndoMT in MRPECs, a specific inhibitor of Notch signaling, GSI, was used. MRPECs were treated with 2 µg/mL rhMMP-9 with or without GSI (0.05 or 0.1 nM/mL). VE-cadherin, NICD and α-SMA expression were measured by western blot. GSI significantly inhibited rhMMP-9-induced NICD and α-SMA expression in a dose-dependent manner, whereas the levels of CD31 and VE-cadherin were not significantly altered (Figure [5](#gfw308F5){ref-type="fig"}A and B). FIGURE 5Inhibition of Notch pathway by GSI reduces rhMMP-9-induced EndoMT in MRPECs. (**A**) Representative western blots of CD31, VE-cadherin, α-SMA and NICD expression in MRPECs treated with rhMMP-9 (2 μg/mL) alone or with GSI (0.05 or 0.1 nM/mL). (**B**) Quantitation of CD31, VE-cadherin, α-SMA and NICD in MRPECs treated with rhMMP-9 (2 μg/mL) alone or with GSI (0.05 or 0.1 nM/mL). Data in bar graphs are means ± SEM (*n* ≥ 3 for each group). \*P \< 0.05 versus MRPECs without rhMMP-9 treatment. ^†^P \< 0.05 versus MRPECs treated with rhMMP-9 only.

MMP-9 deficiency reduces EndoMT and fibrosis in UUO {#s3f}
---------------------------------------------------

We next explored the role of MMP-9 in kidney fibrosis using the UUO model in MMP-9 KO and WT control mice. EndoMT was examined by α-SMA/VE-cadherin double staining and kidney fibrosis was assessed by Gomori trichrome staining. After UUO, marked interstitial α-SMA expression (Figure [6](#gfw308F6){ref-type="fig"}B and E) and kidney fibrosis (Figure [6](#gfw308F6){ref-type="fig"}H and K) in obstructed kidneys were observed in MMP-9 WT mice. In contrast, UUO kidney of MMP-9 KO mice had considerably lower α-SMA levels (Figure [6](#gfw308F6){ref-type="fig"}D and E) \[α-SMA positive area: 12.81 ± 1.30% (MMP-9 KO) versus 25.45 ± 4.42% (MMP-9 WT), P \< 0.05\] and interstitial fibrosis (Figure [6](#gfw308F6){ref-type="fig"}J and K) \[5.66 ± 0.81% (MMP-9 KO) versus 25.20 ± 3.69% (MMP-9 WT), P \< 0.05\]. Importantly, there were significantly fewer peritubular α-SMA/VE-cadherin double positive EndoMT cells in the kidneys of MMP-9 KO mice (Figure [6](#gfw308F6){ref-type="fig"}D and F) than those of WT controls (Figure [6](#gfw308F6){ref-type="fig"}B and F) \[14.78 ± 0.7362 (MMP-9 KO) versus 20.73 ± 1.622 (MMP-9 WT), P \< 0.05\]. These results demonstrate that MMP-9 deficiency contributes to an ∼30% reduction in total α-SMA-positive myofibroblasts arising from EndoMT of peritubular endothelial cells, with another 20% reduction from other sources. FIGURE 6MMP-9 deficiency inhibits EndoMT and kidney fibrosis. (**A**--**D**) Co-localization of peritubular VE-cadherin (green) and α-SMA (red) in kidney sections from sham-operated kidney or UUO kidney of MMP-9 WT (A and B) or MMP-9 KO mice (**C** and **D**). (**E** and **F**) Quantitative analysis of α-SMA-positive area (E) and co-localization of VE-cadherin and α-SMA in kidney sections (F) from sham-operated or UUO kidneys of MMP-9 WT or MMP-9 KO mice. (**G**--**J**) Representative Gomori trichrome staining of kidney sections from sham-operated or UUO kidneys of MMP-9 WT (G and H) or MMP-9 KO (I and J) mice (Gomori trichrome, original magnification ×200). (**K**) Semiquantitative score of tubulointerstitial fibrosis in the cortex of kidney sections from sham-operated or UUO kidneys of MMP-9 WT or MMP-9 KO mice. Data in bar graphs are means ± SEM (*n* ≥ 3 for each group). \*P \< 0.05 versus corresponding sham-control mice. ^†^P \< 0.05 versus MMP-9 WT mice.

MMP-9 deficiency results in reduced expression of Hey-1 in UUO {#s3g}
--------------------------------------------------------------

Hey-1 is a downstream transcription factor of the Notch pathway. To further elucidate the relationship between MMP-9 and Notch signaling in kidney fibrosis, we determined the expression of Hey-1 in the obstructed kidneys of MMP-9 KO and WT control mice by immunofluorescence staining. In comparison with corresponding sham-controls, the expression of interstitial Hey-1 co-localized with α-SMA staining was increased significantly in the obstructed kidney of MMP-9 WT mice. However, no increase in Hey-1 expression was observed in the obstructed kidneys of MMP-9 KO mice (Figure [7](#gfw308F7){ref-type="fig"}). These results provide further evidence for the role of MMP-9 in mediating Notch signaling in kidney fibrosis. FIGURE 7MMP-9 deficiency downregulates Hey-1 expression in UUO. Representative immunofluorescence staining and quantitation of Hey-1 (green) and α-SMA (red) and their tubulointerstitial co-localization with DAPI (blue) in sham-control and obstructed kidneys of MMP-9 WT or MMP-9 KO mice. Original magnification ×200. \*P \< 0.05 versus corresponding sham-control mice. ^†^P \< 0.05 versus MMP-9 WT mice.

DISCUSSION {#s4}
==========

MMP-9 is a zinc-dependent matrix-degrading enzyme with complex biological functions depending on its cellular origins and site of activity. We previously reported that MMP-9 of both tubular and macrophage origin was critical to TGF-β1-induced tubular cell EMT \[[@gfw308C6], [@gfw308C24]\]. It has been confirmed that MMP-9 is necessary for the disruption of epithelial cell basement membrane, a key step to complete the entire course of EMT \[[@gfw308C26]\]. Kidney endothelial cells that underwent EndoMT were recently demonstrated to play a more important role in kidney fibrosis than tubular cells or pericytes \[[@gfw308C5]\]. But the underlying molecular mechanism remains poorly defined. We hypothesized that MMP-9 may also play a role in EndoMT. Our results demonstrated that MMP-9 indeed mediates TGF-β1-induced EndoMT, via activation of the Notch pathway.

Kidney endothelial cells are found in vascular, glomerular and peritubular capillary beds. Although it has been generally accepted that endothelial cells contribute to myofibroblast formation in kidney fibrosis \[[@gfw308C13]\], the roles of the various kidney endothelial cells in kidney fibrosis are not clearly defined. Techniques for isolating glomerular endothelial cells are established \[[@gfw308C27], [@gfw308C28]\], but isolation of peritubular endothelial cells has not been described elsewhere. In this study, we isolated MRPECs by our recently established method \[[@gfw308C6]\], and investigated the roles of MRPECs in kidney fibrosis. We showed that co-localization of endothelial marker VE-cadherin with mesenchymal marker α-SMA in the kidneys of UUO mice was mainly found outside glomeruli (Figure [1](#gfw308F1){ref-type="fig"}F) in the tubulointerstitial space. These results demonstrated that peritubular endothelial cells do contribute to kidney fibrosis. We acknowledge that the co-staining of endothelial with mesenchymal markers in demonstrating EndoMT may underestimate the actual number of EndoMT cells, as endothelial markers are decreased and even lost during EndoMT.

Both MMP-9 and MMP-2 are expressed in endothelial cells of different organs \[[@gfw308C1]\]. However, our *in vitro* results showed that active MMP-9 was significantly increased (Figure [2](#gfw308F2){ref-type="fig"}D), while no MMP-2 activity was observed during TGF-β1-induced EndoMT in MRPECs (data not shown). rhMMP-9 alone was capable of inducing EndoMT in MRPECs. Importantly, MMP-9 inhibitor reduced TGF-β1-induced EndoMT of MRPECs in a dose-dependent manner (Figure [2](#gfw308F2){ref-type="fig"}C). These results suggest that MMP-9 but not MMP-2 contributes to EndoMT of peritubular endothelial cells.

Previously, we showed that the inhibition of MMP-9 activity by an MMP-2/9 inhibitor or MMP-9 neutralizing antibody prevented the development of kidney fibrosis \[[@gfw308C6]\]. Wang *et al.* also reported that ureteral obstruction in MMP-9-deficient mice led to a reduction in tubular cell EMT and hence a decrease in kidney fibrosis \[[@gfw308C29]\]. In addition to promoting EMT of tubular epithelial cells, our present *in vivo* study using MMP-9 KO mouse in UUO model clearly demonstrated that MMP-9 also promotes EndoMT of peritubular endothelial cells and thus contributes to kidney fibrosis (Figure [4](#gfw308F4){ref-type="fig"}A and C).

The Notch family is involved in the differentiation or pathological changes of various types of cells including kidney podocytes and tubular cells \[[@gfw308C30]\]. Notch signaling is markedly reduced in the adult kidney, however, increased Notch signaling has been noted in chronic kidney injury \[[@gfw308C30]\]. Inhibition of the Notch pathway ameliorated diabetic kidney disease, nephrotic syndrome and fibrosis in different rodent models \[[@gfw308C31]\]. Inhibition of Notch activation reduced EMT and consequent kidney fibrosis \[[@gfw308C31]\]. However, whether Notch signaling plays a role in EndoMT is unknown. In the present study, we showed that treatment of MRPECs with rhMMP-9 resulted in the cleavage of Notch-1 (Figure [4](#gfw308F4){ref-type="fig"}A and B). In addition, the activation of Notch-1 was significantly reduced during TGF-β1-induced EndoMT in MMP-9 deficiency (Figure [4](#gfw308F4){ref-type="fig"}A and B). In MRPECs, inhibition of the Notch pathway by GSI reduced rhMMP-9-induced EndoMT, whereas MMP-9 deficiency reduced expression of Hey-1, a downstream transcription factor of Notch signaling (Figure [7](#gfw308F7){ref-type="fig"}).

In summary, we found that MMP-9-dependent Notch signaling plays an important role in kidney fibrosis, at least partly through EndoMT of peritubular endothelial cells. Therefore, pharmacological inhibition of the MMP-9/Notch pathway may serve as an effective approach to prevent kidney fibrosis.
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